Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3627-3639
Open Access | Times Cited: 1005

Showing 1-25 of 1005 citing articles:

2023 ESC Guidelines for the management of cardiomyopathies
Elena Arbelo, Alexandros Protonotarios, Juan R. Gimeno, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3503-3626
Open Access | Times Cited: 1075
2024 ESC Guidelines for the management of chronic coronary syndromes
Christiaan Vrints, Felicita Andreotti, Konstantinos C. Koskinas, et al.
European Heart Journal (2024) Vol. 45, Iss. 36, pp. 3415-3537
Open Access | Times Cited: 525
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
Isabelle C. Van Gelder, Michiel Rienstra, Karina V Bunting, et al.
European Heart Journal (2024)
Open Access | Times Cited: 460
2024 ESC Guidelines for the management of elevated blood pressure and hypertension
John W. McEvoy, Cian P. McCarthy, Rosa María Bruno, et al.
European Heart Journal (2024)
Closed Access | Times Cited: 322
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Mikhail Kosiborod, Mark C. Petrie, Barry A. Borlaug, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 15, pp. 1394-1407
Closed Access | Times Cited: 218
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria
Brendon L. Neuen, Hiddo J.L. Heerspink, Priya Vart, et al.
Circulation (2023) Vol. 149, Iss. 6, pp. 450-462
Open Access | Times Cited: 100
Heart failure with preserved ejection fraction: everything the clinician needs to know
Patricia Campbell, Frans H. Rutten, Matthew M.Y. Lee, et al.
The Lancet (2024) Vol. 403, Iss. 10431, pp. 1083-1092
Closed Access | Times Cited: 58
Heart failure with preserved ejection fraction
Carine E. Hamo, Colette DeJong, Nick Hartshorne‐Evans, et al.
Nature Reviews Disease Primers (2024) Vol. 10, Iss. 1
Closed Access | Times Cited: 41
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 38
2024 update in heart failure
Alberto Beghini, Antonio Maria Sammartino, Z. Papp, et al.
ESC Heart Failure (2024)
Open Access | Times Cited: 35
Comparative study on the predictive value of TG/HDL-C, TyG and TyG-BMI indices for 5-year mortality in critically ill patients with chronic heart failure: a retrospective study
Zijing Zhou, Qiang Liu, Min Zheng, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 33
Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis
Pardeep S. Jhund, Atefeh Talebi, Alasdair Henderson, et al.
The Lancet (2024) Vol. 404, Iss. 10458, pp. 1119-1131
Open Access | Times Cited: 31
Atrial fibrillation burden: a new outcome predictor and therapeutic target
Nina Becher, Andreas Metzner, Tobias Toennis, et al.
European Heart Journal (2024) Vol. 45, Iss. 31, pp. 2824-2838
Open Access | Times Cited: 30
Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes: the FINE-HEART pooled analysis of cardiovascular, kidney, and mortality outcomes
Muthiah Vaduganathan, Gerasimos Filippatos, Brian Claggett, et al.
Nature Medicine (2024) Vol. 30, Iss. 12, pp. 3758-3764
Open Access | Times Cited: 30
Epidemiology and Burden of Heart Failure in Asia
Jiayu Feng, Yuhui Zhang, Jian Zhang
JACC Asia (2024) Vol. 4, Iss. 4, pp. 249-264
Open Access | Times Cited: 28
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure
Stephen J. Greene, Iyanuoluwa Ayodele, Jacob B. Pierce, et al.
JACC Heart Failure (2024) Vol. 12, Iss. 8, pp. 1365-1377
Open Access | Times Cited: 27
Applications of SGLT2 inhibitors beyond glycaemic control
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 8, pp. 513-529
Closed Access | Times Cited: 26
Contemporary pharmacological treatment and management of heart failure
Biykem Bozkurt
Nature Reviews Cardiology (2024) Vol. 21, Iss. 8, pp. 545-555
Closed Access | Times Cited: 25
Anthracycline Cardiotoxicity in Adult Cancer Patients
Massimiliano Camilli, Carlo M. Cipolla, Susan Dent, et al.
JACC CardioOncology (2024) Vol. 6, Iss. 5, pp. 655-677
Open Access | Times Cited: 24
SGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Marco Valerio Mariani, Giovanna Manzi, Nicola Pierucci, et al.
Journal of Cardiovascular Electrophysiology (2024) Vol. 35, Iss. 9, pp. 1754-1765
Closed Access | Times Cited: 23
Current Approaches to Worsening Heart Failure: Pathophysiological and Molecular Insights
Andrea D’Amato, Silvia Prosperi, Paolo Severino, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1574-1574
Open Access | Times Cited: 22
Ferroptosis mechanisms and regulations in cardiovascular diseases in the past, present, and future
Wenxi Fang, Saiyang Xie, Wei Deng
Cell Biology and Toxicology (2024) Vol. 40, Iss. 1
Open Access | Times Cited: 22
Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i—Arrhythmias and Sudden Cardiac Death)
Jia Liao, Ramin Ebrahimi, Zhiyu Ling, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 21
Impact of Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) Therapy on Dementia and Cognitive Decline
Antonio Lardaro, L. Quarta, Stefania Pagnotta, et al.
Biomedicines (2024) Vol. 12, Iss. 8, pp. 1750-1750
Open Access | Times Cited: 19
Diuretic Treatment in Patients with Heart Failure: Current Evidence and Future Directions – Part I: Loop Diuretics
Joseph J. Cuthbert, Andrew L. Clark
Current Heart Failure Reports (2024) Vol. 21, Iss. 2, pp. 101-114
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top